Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in Inflammatory Bowel Disease Patients Treated With Vedolizumab

Trial Profile

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in Inflammatory Bowel Disease Patients Treated With Vedolizumab

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Vedolizumab (Primary) ; Hepatitis B vaccine; Influenza virus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
  • Indications Inflammatory bowel diseases
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 18 Apr 2017 Planned End Date changed from 30 Apr 2018 to 30 Jun 2018.
    • 18 Apr 2017 Planned primary completion date changed from 30 Apr 2018 to 30 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top